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Background/aim: Alzheimer disease (AD) is triggered by interactions of multiple genetic and environmental factors. The APOE gene
E4 allele is the best-known risk factor for AD, yet it represents a small ratio of genetic factors. According to genome-wide association
studies, the BIN1 gene is the second important risk factor for AD, following the APOE gene. We aimed to identify a novel biomarker
indicating susceptibility to AD by investigating APOE alleles and BIN1 gene polymorphisms in a Turkish population.
Materials and methods: Fifty-three AD patients and 56 controls were included to examine polymorphism and allele frequency of the
APOE and BIN1 genes. Genomic DNAs were isolated from whole blood by SDS/proteinase K treatment, phenol-chloroform extraction,
and ethanol precipitation. RFLP was done for identification of polymorphisms in the APOE gene and allele-specific PCR was used for
the BIN1 gene.
Results: Frequency of the APOE E4 allele was higher in the AD patient group, while the frequency of the E2 allele was higher in controls.
The E4/E4 genotype was detected in the AD patient group, while this genotype was not observed in the controls. The frequencies of
BIN1 alleles were similar in both groups.
Conclusion: There was a strong association between AD and the APOE E4 allele, while no such relation was observed with BIN1 gene
polymorphism.
Key words: Alzheimer disease, APOE, BIN1, polymorphism, biomarker, RFLP

1. Introduction
Alzheimer disease (AD) is an age-dependent, irreversible
neurodegenerative disease, of which the most important
risk factor is old age. Its prevalence is doubled with
every 5 years after 65 years of age (1). Clinical diagnosis
of AD is made by exclusion of other causes of dementia.
Its accurate diagnosis is only possible with postmortem
neuropathological examination (2). Therefore, there is a
need for determination of specific biomarkers contributing
to the diagnosis of AD. These biomarkers need to be able
to determine susceptibility to AD as well as establishment
of diagnosis and determination of prognosis; furthermore,
they should also be useful for differential diagnosis from
other causes of dementia (1).
The most important known risk factor for AD is the E4
allele of the apolipoprotein E (APOE) gene, although the
* Correspondence: mehmet.gunduz@gmail.com
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prevalence of this allele in AD in Turkish society varies.
Obviously, this single gene polymorphism is not able to
be an explanatory factor for the pathophysiology of AD,
and the influence of different genes on AD should be
studied in detail. Another important candidate gene in the
pathogenesis of AD identified in genome-wide association
studies (GWASs) is the bridging integrator 1 (BIN1) gene.
β-Amyloid peptide, tau proteins, and the isoform 4 type
of cholesterol transporting APOE protein have been
determined to be involved in the pathogenesis of AD (3,4).
Many candidate genes that are possible risk factors for
AD have been studied and four genes from those (APP,
PSEN1, PSEN2, and APOE) have been reported to be
associated with the disease. Of these, APOE is the bestknown gene to be associated with late-onset AD (LOAD)
(5). According to a GWAS conducted by the Alzheimer’s
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Disease Genetics Consortium, APOE and BIN1 are among
10 genes responsible for susceptibility to LOAD (6).
APOE plays a central role in lipid metabolism and is
involved in the repair of damaged neurons in the central
nervous system (7,8). Therefore, in response to nerve
damage, an apparent increase in levels of APOE is known
to occur (9). APOE has three common isoforms, E2, E3,
and E4 (10,11). First the involvement of APOE E4 in the
pathophysiology of AD was reported (12). In the earliest
works in this area, 62% of AD patients were reported to
be carriers of the E4 allele among autopsied cases, and it
was shown to be a major risk factor in a number of studies
(3,13). In another study, dementia severity was positively
linked to the number of neurofibrillary tangles in the brain,
but not to the degree of senile plaque deposition (14).
A number of studies have determined functions
of BIN1, its polymorphisms related to LOAD, and its
possible physiological effects. Studies also revealed the
involvement of the BIN1 gene and tau protein in AD
risk. The contribution and underlying mechanisms of
the BIN1 gene in the pathogenesis of AD is still not fully
understood; however, many pathways have been discussed.
Further investigations regarding detailed mechanisms
and molecular pathways in AD pathogenesis are of high
importance in terms of understanding LOAD biology and
novel treatment protocols (3,4).
This study aimed to identify certain polymorphisms
that may be effective biomarkers in the detection of
susceptibility to AD in the Turkish population. Therefore,
we aimed to determine the potential biomarkers indicating
the risk of AD in elderly healthy individuals. For this
purpose, healthy individuals and AD patients were
examined for E2, E3, and E4 alleles of the APOE gene and
BIN1 gene polymorphisms.
2. Materials and methods
2.1. Patients
Of the patients admitted to the outpatient clinic of
neurology of Turgut Özal University Hospital, a total of 53
AD patients (29 females, 24 males) ranging in age from 66
to 93 (mean ± SD: 78.28 ± 6.61) and 56 healthy controls
older than 65 years old (36 females, 20 males) ranging in in
age from 65 to 92 (mean ± SD: 72.55 ± 7.92) were included
in the study. The control group members were chosen
from elderly people who had no history or clinical signs
of neurological or psychiatric or cognitive symptoms.
Controls having had surgery or having suffered trauma in
the past 20 days were excluded from the study. Controls
unwilling or unable to fulfill the requirements of the study
were also excluded from the study. Their Mini-Mental State
Examination (MMSE) scores were well above the limit
for the normal cognitive level and not satisfying DSMIV criteria. The study was approved by the Local Ethics

Committee of Turgut Özal University Medical School
(29 January 2013, no. 16). After informed consent was
obtained, neurological examination and the MMSE were
performed for all participants (15). AD was diagnosed
following the criteria for probable AD according to the
National Institute of Neurological and Communicative
Disorders and Stroke and Alzheimer’s Disease and Related
Disorders Association (NINCDS-ADRDA) (16) and the
DSM-IV. Disease severity was evaluated using MMSE
scores; severe AD patients have a score of 16 or lower.
The MMSE scores of the control group were well above
the limit for the normal cognitive level and not satisfying
DSM-IV and NINCDS-ADRDA criteria for diagnosis of
AD.
2.2. DNA isolation
Blood samples from the antecubital vein were taken into
EDTA-containing tubes and were stored at 4 °C for the
short term and –70 °C for the long term until the DNA
isolation procedure. Genomic DNAs were isolated from
whole blood by SDS/proteinase K treatment, phenolchloroform extraction, and ethanol precipitation.
Briefly, 9 mL of lysis buffer (1X RBC lysis buffer) was
mixed with 3 mL of peripheral blood. After obtaining
a pellet by centrifuging at 2000 × g for 10 min, TE was
added and mixed. After adding 10% SDS and proteinase
K, samples were vortexed and incubated at 70 °C for
15 min. They were then incubated overnight at 37 °C.
Following overnight incubation, complete dissolution
of pellets was achieved and samples were centrifuged for
15 min at 5000 rpm. After obtaining supernatant, 20 µL
of 5 M NaCl and 400 µL of phenol (Sigma P4557, USA)
was added, followed by centrifugation at 15,000 rpm for
15 min at 4 °C. Two phases were detected and the upper
transparent phase was transferred to a clean Eppendorf
tube. Later, 400 µL of chloroform in isoamyl alcohol (CIA,
1/25 ratio; Sigma C0549-1PT, USA) was added and tubes
were turned upside-down quickly. This was centrifuged
at 15,000 rpm for 15 min at 4 °C. Two phases were
detected and the upper transparent phase was transferred
to a clean Eppendorf tube. This step was repeated twice.
After centrifugation, the upper transparent phase was
transferred to a clean Eppendorf tube. Consequently, 1
mL of 100% ethanol was added and the DNA pellet was
obtained through centrifugation at 15,000 rpm for 15 min
at 4 °C. The obtained DNA was rinsed with 1 mL of 75%
ethanol and centrifuged at 15,000 rpm for 5 min at 4 °C.
After centrifugation, the ethanol supernatant was removed
and the DNA was left to dry for 10–15 min. Finally,
dissolution of DNA was achieved by adding 100 µL of 1
mM TE buffer. The concentration of DNA was measured
by a spectrophotometer and it was stored at 4 °C.
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2.3. DNA amplification
To study polymorphisms rs429358 T>C and rs7412
C>T, a 303-bp length of the APOE gene was amplified.
The primers of the APOE gene for PCR amplification
were modified from a previous report as follows: 5’
CGGGCACGGCTGTCCAAGGAG 3’ (forward) and
5’ CTGGTGGAACAGGGCCGCGTG 3’ (reverse)
(17). The polymorphism analysis of the BIN1 gene at
rs744373 T>C for a length of 766 bp was performed using
allele specific oligonucleotide (ASO)-PCR and primers
5’ CCATCTTCTTCTGCTCTCCCAG 3’ (forward),
5’ ATGCCTCCTCTCTCCGTCTT 3’ (reverse), 5’
AGGGACAGGCAGGTCTGAGGCC 3’ (forward variant),
and 5’ TCTCAGAGGCTGCCCATG 3’ (reverse wild) as
previously reported (18). The stock solution (100 pmol/
µL) was prepared from lyophilized primers using 1X TE.
The working primers for PCR amplification were prepared
as 20 pmol/µL from stock solution.
2.4. Gradient PCR
Gradient PCR was performed to determine and modify
the optimum temperature for annealing of primers for
the APOE and BIN1 genes. In the reaction Eppendorf
tubes, the total volume used in gradient PCR was 25 µL
comprising 10X buffer, MgCl2 (25 mM), dNTP, primers,
H2O, Taq polymerase, and DMSO. The DNA samples were
added at the end of all procedures. Total gradient PCR mix
was constituted by 10X buffer (2.5 µL), MgCl2 (2.5 µL),
dNTP (0.5 µL), forward primer (0.5 µL), reverse primer
(0.5 µL), Taq polymerase (0.2 µL, 1.0 U/25 µL reaction
mixture), DMSO (1 µL), H2O (15.3 µL), and DNA (2 µL)
for the APOE and BIN1 genes. Reaction conditions for
APOE involved an initial denaturation of DNA at 94 °C for
5 min, followed by 38 cycles of amplification at 94 °C for 30
s (melting), 71 °C for 30 s (annealing), and 72 °C for 1 min,
and final extension at 72 °C for 5 min. Reaction conditions
for BIN1 involved the same procedures for APOE except
the annealing temperature (it was 64 °C).
2.5. Restriction fragment length polymorphism (RFLP)
PCR products provide the sequence of polymorphism
sites for RFLP analysis. Detection of single nucleotide
polymorphism alleles was done using restriction enzymes
recognizing these regions. Enzymatic fragmentation
was performed following the control of amplification
of PCR products by agarose gel electrophoresis. After
fragmentation, 15 µL of DNA was mixed with 1 µL of 6X
loading dye and loaded into the well and run at 100 V for
45 min, followed by visualization in a UV transilluminator.
For enzymatic digestion of APOE gene rs429358 T>C
and rs7412 C>T polymorphisms, a 303-bp PCR product
was fragmented into fragments of 91, 83, 72, and 48 bp
using CFO1 (Hhal) enzyme (New England Biosystems,
USA). The enzyme sliced “C base” from the region of
the “GCGC” sequence. The Hhal enzyme recognition
sequence was 5’..GCG ’C…3’, 3’…C’GCG…5’.
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Risk determinations based on alleles are as follows:
APOE E2 allele (rs429358 (T) + rs7412 (T)); APOE E3
allele (rs429358 (T) + rs7412 (C) = most common allele);
APOE E4 allele (rs429358 (C) + rs7412 (C) = risk for AD);
APOE E4/E4 allele (rs429358 (C;C) + rs7412 (C;C) = high
risk for AD). Genotyping is as follows: E2/E2 (91 bp + 83
bp), E3/E3 (91 bp + 48 bp), E4/E4 (72 bp + 48 bp), E2/E3
(91 bp +83 bp +48 bp), E2/E4 (91 bp + 83 bp + 72 bp + 48
bp), E3/E4 (91 bp + 72 bp + 48 bp). Thus, polymorphic
APOE includes three major isoforms: APOE E2 (cys112,
cys158), APOE E3 (cys112, arg158), and APOE E4 (arg112,
arg158).
2.6. ASO-PCR
After optimization trials, the total ASO-PCR reaction
mixture was prepared to be 25 µL for each sample. Mixtures
comprising 10X buffer, MgCl2 (25 mM), dNTPs, primers,
H2O, DMSO, and Taq polymerase were distributed into
each reaction tube, and finally DNA samples were added.
Unlike normal PCR, two different specifically designed
primers were used in ASO-PCR. The only difference in
these primers was that one included the variant C allele
primer, while the other included the wild-type T allele
instead.
PCR products of APOE and BIN1 were confirmed
by 2% agarose gel electrophoresis. However, for RFLP
fragment analysis of the APOE gene, 4% agarose gel was
used.
2.7. Sequencing
In order to confirm the RFLP and ASO-PCR results, the
sequencing of some samples was conducted as follows.
First 2 µL of ExoSAP IT (GML A.G., Switzerland) was
placed into PCR tubes, and then 5 µL of PCR product was
added and tubes were placed in a thermal cycler. Reaction
conditions for the presequence procedure involved an
initial denaturation of DNA at 37 °C for 30 min, followed
by final extension at 80 °C for 15 min and storage at 4 °C.
A mixture prepared for this purpose (8 µL) was placed
into each tube and 2 µL of DNA-treated ExoSAP was
added. As a control, pGEM was used. Reaction conditions
for the sequence involved an initial denaturation of DNA
at 96 °C for 1 min, followed by 25 cycles of amplification at
96 °C for 15 s (melting), 50 °C for 15 s (annealing), and 60
°C for 4 min, with no more final extension. PCR products
were purified using Sephadex column purification after
sequencing PCR amplification. Samples were analyzed
with the Applied Biosystems 3130 Genetic Analyzer.
2.8. Statistical evaluation
SPSS 16.0 was used for assessment of the relationship
between genotypes and clinical findings. The chi-square
test and Fisher’s exact test were used as needed for
comparisons between allele and genotype frequencies of
patients and controls. P < 0.05 was considered significant.
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3. Results
3.1. APOE PCR electrophoresis and Hhal enzyme
digestion
For evaluation of PCR products of the searched region for
APOE, samples were run on 2% agarose gel (fragments of
303 bp in length) and visualized in a UV transilluminator
(Figure 1).
In order to assess RFLP results of the investigated
region, enzyme digestion fragments were run on 4%
agarose gel, and fragments of 91 bp, 83 bp, 72 bp, and 48
bp were visualized in a UV transilluminator (Figure 2).
3.2. BIN1 PCR electrophoresis results
To evaluate PCR products of the investigated region, ASOPCR products were run on 2% agarose gel, and fragments
of 766 bp, 498 bp, and 308 bp were obtained and visualized
in a UV transilluminator (Figure 3).
3.3. Sequence confirmation
After detecting the presence of PCR products, certain
reference samples underwent DNA sequencing, and the
BIN1 and APOE genes were confirmed. PCR products
were purified using Sephadex column purification after
PCR amplification. Samples were analyzed with the 3130
Genetic Analyzer. APOE gene polymorphism results
were as follows: E2/E3 polymorphism (Figure 4), E3/
E4 polymorphism (Figure 5), and E3/E3 polymorphism
(Figure 6). PCR polymorphism results of BIN1 were
defined as TT and CT polymorphisms (Figure 7).
3.4. Allele distributions of APOE and BIN1 genes
APOE and BIN1 allele distributions of patient and control
groups are shown in Table 1. APOE allele distribution
percentages in AD patients were determined as follows:
58.5% for E3/E3, 5.7% for E4/E4, 7.5% for E2/E3, 0% for
E2/E4, and 28.3% for E3/E4. APOE allele distribution
percentages in the control group were determined as
follows: 67.9% for E3/E3, 0% for E4/E4, 17.9% for E2/
E3, 1.8% for E2/E4, and 12.5% for E3/E4. The difference
between the prevalence of the E4 allele in AD patients

and the control group was statistically significant (P
< 0.05) (Table 2). Regarding BIN1 allele distribution,
there was no statistically significant difference for CC
genotype prevalence between patients and controls (P >
0.05). E2 allele prevalence was significantly higher in the
control group compared to AD patients (P = 0.067). Sex
distribution ratios and its relationship with APOE and
BIN1 were similar between the patient and control groups
(Table 3) (P > 0.05).
Although a statistically significant difference was
observed between patient and control groups in terms of
ischemic heart disease prevalence, there was no significant
difference in terms of prevalence of hypertension,
diabetes, stroke history, cholesterol and triglyceride levels,
and family history of AD (Table 4). Furthermore, no
statistically significant difference was observed between
patient and control groups in terms of the relationship of
APOE genotype with cholesterol, stroke history, ischemic
heart disease, triglyceride levels, and family history of
AD (P > 0.05) (Table 5). There was significant difference
between patient and control groups in terms of relationship
of APOE E4 allele with hypertension, while no significant
difference was observed in terms of relationship of APOE
E4 allele with stroke history, ischemic heart disease,
diabetes, and family history of AD (P > 0.05) (Table 5).
There was a statistically significant difference between
patient and control groups in terms of relationship of BIN1
gene CC allele with hypertension prevalence (P < 0.001)
(Table 6); however, no significant difference was observed
in terms of diabetes, family history of AD, cholesterol
and triglyceride levels, stroke history, or ischemic heart
disease (P > 0.05). The distribution of APOE gene E4 allele
and BIN1 C allele frequencies and their relationship with
MMSE scores in AD patients is shown in Table 7.
4. Discussion
In this study we investigated rs429358 and rs7412
polymorphisms for E2, E3, and E4 alleles of the APOE

Figure 1. Agarose gel image of APOE PCR amplification products.
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Figure 2. Agarose gel image of APOE RFLP products.

Figure 3. Agarose gel image of BIN1 ASO-PCR amplification products.
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CT
HETEROZYGOTE

AA
HOMOZYGOTE

Figure 4. APOE Rs429358 and Rs7412 polymorphisms.

GG
HOMOZYGOTE

GA
HOMOZYGOTE

Figure 5. a) APOE rs429358 and b) APOE rs7412 polymorphisms.
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GG
HETEROZYGOTE

AA
HOMOZYGOTE

Figure 6. a) APOE rs429358 and b) APOE rs7412 polymorphisms.

Figure 7. BIN1 gene rs744373 polymorphism.
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Table 1. APOE and BIN1 allele distributions in AD and control groups.

Groups

APOE allele

BIN1 allele

E3/E3

E4/E4

E2/E3

E2/E4

E3/E4

Total

TT

CC

TC

Total

AD patients

31 (58.5%)

3 (5.7%)

4 (7.5%)

0 (0%)

15 (28.3%)

53 (100%)

35 (66%)

3 (5.7%)

15 (28.3%)

53 (100%)

Controls

38 (67.9%)

0 (0%)

10 (17.9%)

1 (1.8%)

7 (12.5%)

56 (100%)

34 (60.7%)

3 (5.4%)

19 (33.9%)

56 (100%)

Total

69 (63.3%)

3 (2.8%)

14 (12.8%)

1 (0.9%)

22 (20.2%)

109 (100%) 69 (63.3%)

6 (5.5%)

34 (31.2%)

109 (100%)

Table 2. Distribution of APOE gene E4 and E2 allele frequencies.

Groups

APOE allele
E4 allele

Others

Total

P-value

AD patients

18 (34%)

35 (66%)

53 (100%)

Controls

8 (14.3%)

48 (85.7%)

56 (100%)

Total

26 (23.9%)

83 (76.1%)

109 (100%)

P = 0.016*

E2 allele

Others

Total

P-value

4 (7.5%)

49 (92.5%)

53 (100%)

11(19.6%)

45 (80.4%)

56 (100%)

15 (13.8%)

94 (86.2%)

109 (100%)

P = 0.067*

*Pearson chi-square.
Table 3. Distribution of APOE and BIN1 gene allele frequencies with respect to sex.
APOE

Study groups
AD patients

Control

Female

29 (54.7%)

36 (64.3%)

Male

24 (45.3%)

20 (35.7%)

Total

53 (100%)

56 (100%)

P-value
P = 0.309*

E4 allele

E2 + E3 allele

12 (18.5%)

53 (81.5%)

14 (31.8%)

30 (68.2%)

26 (23.9%)

83 (76.1%)

P-value

P = 0.108*

BIN1
CC+CT

TT

Female

26 (65%)

39 (56.5%)

Male

14 (35%)

30 (43.5%)

Total

40 (100%)

69 (100%)

P-value

P = 0.385*

*Pearson chi-square.

gene, which is the most crucial biomarker indicating the
risk of AD during the aging of healthy individuals. We also
investigated the rs744373 polymorphism of BIN1, one of
the most important candidate genes recently identified
in GWASs for AD. The present study is the first study
to investigate BIN1 polymorphism as well as these two
polymorphisms together in Turkey. Findings obtained in
this study can be summarized as follows:
1. AD patient and control groups were similar in terms
of sex distribution and family history for AD.

2. The frequency of APOE E4 allele was higher in the
AD patient group, while the frequency of the E2 allele was
higher in the control group.
3. The E4/E4 genotype was detected in the AD patient
group, while this genotype was not observed in the control
group.
4. The prevalence of ischemic heart disease was
significantly higher in the control group. Since the case
number in our study is relatively low, this finding needs to
be confirmed with further studies.
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Table 4. Distribution of frequencies of comorbid conditions*.
Comorbid conditions

AD patients

Control

Total

P-value

Ischemic cardiac disease

10 (38.5%)

16 (61.5%)

26 (100%)

P = 0.035§

High cholesterol level

2 (6.7%)

10 (29.4%)

12 (18.8%)

P = 0.020§

Hypertension

39 (79.6%)

31 (70.5%)

70 (75.3%)

P = 0.308§

Diabetes

15 (30.6%)

11 (25.6%)

26 (28.3%)

P = 0.593§

History of stroke

7 (14.3%)

8 (18.2%)

15 (16.1%)

P = 0.610§

High

8 (26.7%)

10 (29.4%)

18 (28.1%)

Normal

22 (73.3%)

24 (70.6%)

46 (71.9%)

P = 0.807§

5 (25%)

4 (66.7%)

9 (34.6%)

P = 0.138¶

Triglyceride
Family history of AD

Pearson chi-square.
Fisher’s exact test.
*Some patients and control subjects had more than one disease. In the control group, there were 20 participants without any disease,
14 participants with only one disease (11 hypertension, 1 ischemic heart disease, 1 history of stroke, 1 triglyceride), 8 participants with
two diseases (1 high cholesterol + hypertension, 1 high cholesterol + ischemic heart disease, 1 ischemic heart disease + diabetes, 3
ischemic heart disease + hypertension, 2 diabetes + hypertension), 6 participants with three diseases (2 history of stroke + diabetes +
hypertension, 1 ischemic heart disease + history of stroke + hypertension, 2 triglyceride + hypertension + high cholesterol, 1 triglyceride
+ hypertension + ischemic heart disease), and 8 participants with four or more diseases (1 diabetes + hypertension + high cholesterol
+ triglyceride, 2 diabetes + hypertension + ischemic heart disease + history of stroke, 2 hypertension + high cholesterol + triglyceride
+ ischemic heart disease + history of stroke, 2 hypertension + high cholesterol + triglyceride + ischemic heart disease + diabetes, 1
hypertension + high cholesterol + triglyceride + ischemic heart disease + history of stroke + diabetes). In the patient group, there
were 11 patients without any other diseases, 18 patients with only one disease (17 hypertension, 1 diabetes), 14 patients with two
other diseases (4 diabetes + hypertension, 1 high cholesterol + hypertension, 1 triglyceride + hypertension, 4 ischemic heart disease +
hypertension, 2 history of stroke + hypertension, 2 triglyceride + diabetes), 6 patients with three diseases (3 diabetes + hypertension +
triglyceride, 1 ischemic heart disease + history of stroke + hypertension, 1 ischemic heart disease + diabetes + hypertension, 1 history of
stroke + diabetes + hypertension), and 4 patients with four or more other diseases (2 diabetes + hypertension + ischemic heart disease +
history of stroke, 1 hypertension + ischemic heart disease + history of stroke + triglyceride, 1 diabetes + hypertension + ischemic heart
disease + triglyceride + high cholesterol).
§

¶

5. No significant difference was observed between
patient and control groups in terms of prevalence of
hypertension, diabetes, history of stroke, or triglyceride
levels.
6. The number of individuals with high cholesterol
levels was significantly higher in the control group;
however, there was no statistically significant relationship
between APOE genotypes and cholesterol levels.
7. In both groups, the prevalence of hypertension
was high among cases with the APOE E4 allele, while no
significant difference was observed for diabetes, stroke
history, high cholesterol, triglyceride levels, and ischemic
heart disease.
8. There was no significant relationship between the
frequencies of all APOE genotypes and triglyceride levels,
stroke history, and ischemic heart disease in either group.
9. No statistically significant difference was observed
between patient and control groups in terms of the
frequencies of BIN1 alleles.
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10. There was no relationship between BIN1 genotypes
and family history of AD in either group.
11. The prevalence of hypertension was significantly
lower in individuals with the C allele of the BIN1 gene
in both groups; however, no significant relationship was
observed between C allele frequency and diabetes, high
cholesterol, triglyceride levels, stroke history, and ischemic
heart disease.
12. The relationships between APOE and BIN1 alleles
and MMSE scores in AD patients were given in the present
study for the first time in the literature (Table 7). This is
important because MMSE scores take into consideration
when doctors decide if drugs will help AD patients in
neurology and psychiatry clinics. It is possible to compare
the allele distribution and MMSE scores in Table 7.
Obtained findings suggest that there is a strong
relationship between the E4 allele of APOE and AD, while
there is no significant relationship between the rs744373
polymorphism of the BIN1 gene and AD. Several different
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Table 5. The relationships of APOE genotype and APOE E4 and other gene allele genotypes with certain comorbid conditions.
APOE (columns a)

Comorbid conditions

Ischemic cardiac
disease

High cholesterol
(for columns a only) /
Hypertension
(for columns b only)

History of stroke

Triglyceride
(for columns a only) /
Diabetes
(for column b only)

Family history of AD

APOE E4 and others (columns b)
E4 allele

Other
alleles

Total

26
(100%)

5
(19.2%)

21
(80.8%)

26
(100%)

14
(20.9%)

67
(100%)

18
(26.9%)

49
(73.1%)

67
(100%)

1
(1.1%)

19
(20.4%)

93
(100%)

23
(24.7%)

70
(75.3%)

93
(100%)

1
(8.3%)

-

1
(8.3%)

12
(100%)

21
(30%)

49
(70%)

70
(100%)

1
(1.9%)

6
(11.5%)

-

11
(21.2%)

52
(100%)

2
(8.7%)

21
(91.3%)

23
(100%)

44
(68.8%)

1
(1.6%)

7
(10.9%)

-

12
(18.8%)

64
(100%)

23
(24.7%)

70
(75.3%)

93
(100%)

Positive

10
(66.7%)

0
(0%)

3
(20%)

0
(0%)

2
(13.3%)

15
(100%)

2
(13.3%)

13
(86.7%)

15
(100%)

Negative

49
(62.8%)

3
(3.8%)

9
(11.5%)

1
(1.3%)

16
(20.5%)

78
(100%)

20
(25.6%)

58
(74.4%)

78
(100%)

Total

59
(63.4%)

3
(3.2%)

12
(12.9%)

1
(1.1%)

18
(18.4%)

93
(100%)

22
(23.7%)

71
(76.3%)

93
(100%)

Positive

13
(72.2%)

0
(0%)

2
(11.1%)

-

3
(16.7%)

18
(100%)

4
(15.4%)

22
(84.6%)

26
(100%)

Negative

31
(67.4%)

1
(2.2%)

5
(10.9%)

-

9
(19.6%)

26
(100%)

18
(27.3%)

48
(72.7%)

66
(100%)

Total

44
(68.8%)

1
(1.6%)

7
(10.9%)

-

12
(18.8%)

64
(100%)

22
(23.9%)

70
(76.1%)

92
(100%)

Positive

5
(55.6%)

1
(11.1%)

0
(0%)

-

3
(33.3%)

9
(100%)

4
(44.4%)

5
(55.6%)

9
(100%)

Negative

12
(70.6%)

0
(0%)

2
(11.8%)

-

3
(17.6%)

17
(100%)

3
(17.6%)

14
(82.4%)

17
(100%)

Total

17
(65.4%)

1
(3.8%)

2
(7.7%)

-

6
(23.1%)

26
(100%)

7
(26.9%)

19
(73.1%)

26
(100%)

E3/E3

E4/E4

E2/E3

E2/E4

E3/E4

Total

Positive

18
(69.2%)

0
(0%)

3
(11.5%)

0
(0%)

5
(19.2%)

Negative

40
(59.7%)

3
(4.5%)

9
(13.4%)

1
(1.5%)

Total

58
(62.4%)

3
(3.2%)

12 (12.9%)

Positive

10
(83.3%)

0
(0%)

Negative

34
(65.4%)

Total

P-value

P = 0.754*

P = 0.652*

P = 0.767*

P = 0.920*

P = 0.286*

P-value

P = 0.444*

P = 0.040*

P = 0.508**

P = 0.229*

P = 0.188**

*Pearson chi-square.
**Fisher’s exact test.

findings were obtained in the present study when compared
to previously conducted studies. These differences were
probably caused by case series with different case numbers
and characteristics, genetic and environmental factors
affecting cases, and ethnic origins of cases.
In the pathophysiology of AD, APOE interacts with tau
protein and amyloid β, and it affects neurofibrillary tangles
and senile plaques. In vitro studies revealed that unlike
the E3 allele of APOE, E4 forms a highly stable complex

with amyloid β and the number, diameter, and density of
immunoreactive plaques are found to be associated with
APOE genotype (19). Amyloid β plaques are known to
be more common and bigger in individuals carrying the
E4/E4 allele compared to those individuals with the E3/
E3 allele. In accordance with this, the E4/E4 genotype was
detected in the AD patient group, while this genotype was
not observed in the control group in the present study.
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Table 6. The relationship of BIN1 gene alleles with certain comorbid conditions.
BIN1

Comorbid conditions
CC + CT

Family history of AD

Hypertension

Diabetes

Triglyceride

High cholesterol level

Ischemic cardiac disease

History of stroke

P-value

TT

Total

Positive

3 (33.3%)

6 (66.7%)

9 (100%)

Negative

6 (35.3%)

11 (64.7%)

17 (100%)

Total

9 (34.6%)

17 (65.4%)

26 (100%)

Positive

17 (24.3%)

53 (75.7%)

70 (100%)

Negative

15 (65.2%)

8 (34.8%)

23 (100%)

Total

32 (34.4%)

61 (65.6%)

93 (100%)

Positive

10 (38.5%)

16 (61.5%)

26 (100%)

Negative

22 (33.3%)

44 (66.7%)

66 (100%)

Total

32 (34.8%)

60 (65.2%)

92 (100%)

High

9 (50%)

9 (50%)

18 (100%)

Normal

14 (30.4%)

32 (69.6%)

46 (100%)

Total

23 (35.9%)

41 (64.1%)

64 (100%)

Positive

4 (33.3%)

8 (66.7%)

12 (100%)

Negative

19 (36.5%)

33 (63.5%)

52 (100%)

Total

23 (35.9%)

41 (64.1%)

64 (100%)

Positive

9 (27.3%)

17 (28.3%)

26 (28%)

Negative

24 (72.7%)

43 (71.7%)

67 (72%)

Total

33 (100%)

60 (100%)

93 (100%)

Positive

3 (9.4%)

12 (19.7%)

15 (16.1%)

Negative

29 (90.6%)

49 (80.3%)

61 (100%)

Total

32 (100%)

61 (100%)

93 (100%)

P = 1.000**

P = 0.000*

P = 0.642*

P = 0.142*

P = 1.000**

P = 0.913*

P = 0.200*

*Pearson chi-square.
**Fisher’s exact test.
Table 7. The frequencies of APOE gene E4 allele and BIN1 gene C allele with respect to MMSE test scores in AD patients.
APOE

BIN1

MMSE score

E4 allele

Other alleles

Total

CC-CT

TT

Total

5–10

0 (0%)

2 (100%)

2 (100%)

1 (50%)

1 (50%)

2 (100%)

10–15

3 (50%)

3 (50%)

6 (100%)

2 (33.3%)

4 (66.7%)

6 (100%)

15–20

4 (40%)

6 (60%)

10 (100%)

3 (30%)

7 (70%)

10(100%)

20–25

7 (38.9%)

11 (61.1%)

18 (100%)

5 (27.8%)

13 (72.2%)

18 (100%)

>25

0 (0%)

3 (100%)

3 (100%)

1 (33.3%)

2 (66.7%)

3 (100%)

Total

14 (35.9%)

25 (64.1%)

39 (100%)

12 (30.8%)

27 (69.2%)

39 (100%)
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The E3 allele of APOE is the most common form and
anticipated as the main form. In the pathophysiology of
AD, APOE E4 is accepted as a risk factor, while APOE E2
is considered a protective factor in some studies (20). It has
also been shown that the E2 allele has no protective effect
on AD, or was related to a nonsignificantly decreased
risk of the disease. Therefore, both alleles (E2 and E3)
are not considered as risk factors for AD while E4 has
been considered as a high risk factor for AD (21). This
conclusion of other studies is confirmed by our findings
in the present study.
A number of studies dealing with APOE allele frequencies
in AD patients revealed that the E2/E2 allele genotype is
not observed in AD patients, while the E4/E4 allele is quite
rare or absent in controls, similar to the present study (22–
26). The comparison of frequencies of APOE alleles with
the literature is shown in Table 8. Several studies showed
significantly higher E4 allele rates in AD patients compared
to controls (27–29). Furthermore, a great number of studies
from different parts of the world such as Tunisia (17),
Germany (30), France (31), Canada (32), Greece (33), Japan
(34), three regions of Italy (Sicily, Sardinia, Apulia) (35–37),
Iran (38), Spain (39), Korea (40), and China (41) revealed
identical results to the present study. Similarly, in the present
study the frequency of the E4 allele was significantly higher
in the AD patient group compared to controls (P < 0.05).
Furthermore, there was no E4/E4 genotype in the control
group, while it was observed in AD patients, which proves
that APOE E4 is a susceptibility gene for AD, in accordance
with the literature. Unlike a large number of studies from
the literature, there are studies claiming that the APOE E4
allele is not a risk factor for AD. These studies have dealt
with AD patient series from Kenya (42), Nigeria (43), and
Africans living in Cameroon and the Nile region (44).
Furthermore, these were supported by studies dealing with
African Americans and Spanish Americans (45,46). These
controversial results might suggest that the AD-associated
APOE E4 allele could be affected and altered by other active

genes and the potential environmental effects as well as
ethnic factors (47).
Unlike the present study, certain studies showed the
existence of the E2/E2 genotype both in AD patients and
controls; however, these studies revealed higher frequency
of the E4/E4 genotype in AD patients, in accordance with
our study (48,49). Our study shows the effective nature
of the E4 allele in the development of AD, similar to the
related literature. On the other hand, our study supports
the literature indicating the E2 allele as a protective factor
for AD.
One of the many risk factors for development of LOAD
is the familial history of AD and the E4 allele (50,51). In
accordance with the literature, the frequency of the E4
allele of the APOE gene was higher in individuals with a
family history of dementia in the present study.
There are studies revealing significant correlations
between sex and the frequency of the E4 allele (41,52,53).
However, the sex distribution between AD patient and
control groups was similar (P = 0.309) and no significant
relationship was observed between sex and the frequency
of the E4 allele of APOE (P = 0.108) in our study. The
incidence of AD increases with age, and this statement was
supported by our study, as well. A series of studies from
North Africa showed that an increase in aged population
(from 4.1% in 1956 to 9.6% in 2004) coincided with
increased incidence of AD (17,54).
AD is thought to have a multifactorial etiology and the
exact mechanism still needs to be explained. Therefore,
this study also compared AD patient and control groups
in terms of comorbid medical conditions, which might
contribute to the development of AD. A significant
difference was observed between AD patient and control
groups in terms of comorbid ischemic heart disease and
high cholesterol level (P < 0.05). Furthermore, there was
statistically significant correlation between the E4 allele of
the APOE gene and hypertension (P < 0.05). In general,
comorbidity describes the effect of all diseases that we

Table 8. The comparison of frequencies of APOE alleles with the literature.
APOE allele
Reference

AD patients

Controls

E2/E2

E3/E3

E4/E4

E2/E3

E2/E4

E3/E4

E2/E2

E3/E3

E4/E4

E2/E3

E2/E4

E3/E4

(17)

-

35.0%

17%

4.0%

9.0%

35.0%

1%

68.0%

2%

10%

3.0%

16.0%

(18)

-

74.3%

2.9%

5.7%

2.9%

14.3%

-

93.1%

-

3.4%

-

3.4%

(19)

-

63.2%

-

7.4%

-

29.4%

-

71.7%

-

11.8%

0.8%

15.7%

(20)

-

53%

5.0%

1.0%

-

41.0%

-

72.0%

3.0%

7.0%

2.0%

16.0%

58.5%

5.7%

7.5%

-

28.3%

-

67.9%

-

17.9%

1.8%

12.5%

Current study -
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inspected on AD in this study. These results suggest an
insight into the relationships between AD, ischemic heart
disease, and high cholesterol levels as well as a strong
correlation between the E4 allele of the APOE gene and
hypertension. Because the presence of comorbidity must
be taken into account when selecting the diagnosis and
treatment plans for AD patients, our findings are worth
considering for clinicians who follow patients with AD.
According to strong evidence, it has been suggested that
AD shares characteristics and possible origins with both
cardiovascular disorders and diabetes (55). We did not find
such a comorbidity correlation between the occurrence of
AD and diabetes.
In the current study, the genotype distribution of BIN1
in the AD patient group was as follows: 66% for TT, 5.7%
for CC, and 28.3% for TC. In the control group it was as
follows: 60.7% for TT, 5.4% for CC, and 33.9% for TC. The
frequency of the C allele and CC genotype did not show
significant difference (P > 0.05) between AD patient and
control groups, and no significant difference was observed
between the groups at all. However, there are previously
conducted studies indicating the significance of BIN1
in the literature (56). Since different genetic variants of
BIN1 might cause an alteration in the way of progression
of AD, and only one single nucleotide polymorphism is
not sufficient to estimate genetic risks for AD, multilocus
genotype patterns might provide a novel analytical
approach for genetic risk estimation of AD.
In a study dealing with APOE risk-free series, the odds
ratio and the population attributable fraction of single
nucleotide polymorphisms of BIN1 were estimated to be
1.2% and 6%, respectively (57). This is partially supported
our work. In the literature, BIN1 expression was shown to
change in brains suffering from AD in transgenic mouse
models of AD (58). Furthermore, BIN1 expression was
reported to be associated with age of onset and duration
of illness (59). In this study we investigated the relation
of different genotypes of BIN1 and certain medical

conditions, and we observed a significant relationship
between the C allele of the BIN1 gene and hypertension
incidence (P < 0.001).
There are very little data regarding the relationship
between the BIN1 gene and neurodegeneration, while
there are plentiful data regarding roles of APOE,
clusterin (CLU), and complement receptor 1 (CR1) in
AD. Therefore, the role of BIN1 and potential molecular
pathways in the pathogenesis of AD need further
investigation. Additionally, understanding the BIN1 roles
in other pathways possibly associated with AD might help
us to elucidate its role in AD pathogenesis. A recent study
showed that BIN1 increases the risk of AD by interacting
with tau protein and by affecting neurofibrillary tangles
(60–62). However, further studies are needed to determine
the mechanism of interaction between BIN1 and tau,
and neurofibrillary tangles, which might be promising
for novel treatment approaches. Additionally, epigenetic
regulation in the expression of BIN1 or methods used
for decrease of amyloid β production can be used as new
treatments for AD. On the other hand, studies identifying
novel molecules and pathophysiological pathways will
surely contribute to the development and implementation
of more effective treatment procedures.
In conclusion, the obtained results, in addition to
the previously conducted genetic studies, showed that
AD is not caused by a single etiological factor, but there
are multiple risk factors playing roles in its etiology. As
a limitation, our study has a small scale. Especially in
terms of representing the whole of Turkey, a larger-scale
study dealing with patient series from different provinces
of Turkey and investigating more candidate genes and
polymorphisms should be performed.
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